An analysis of phosphorylated tau (p-tau) isoforms isolated from CSF-derived EVs have identified high levels of p-T181-tau/T181 in AD patients at early stages of disease that decrease at later stages (Saman et al., 2012). The gene discussed is MAPT; the disease is Alzheimer disease.